Comparison of hazards for acute myocardial infarction, stroke, cardiovascular-related mortality, major adverse cardiovascular event, all-cause mortality, venous thromboembolism, arterial thromboembolism, and cancer between the Janus kinase inhibitor and tumor necrosis factor inhibitor groups. This evidence concerns the gene TNF and stroke disorder.